Seed Round Open | $1.5M Target | Early Investor Commitments Secured

Bringing Speed and Certainty to Forensic DNA Testing

We deliver rapid, affordable, and accessible DNA testing solutions, empowering laboratories worldwide with speed and certainty.

 

 

 

Join us in our Seed Round
Hero Slide 01
A GLOBAL NEED, URGENTLY UNMET

A Problem Worth Solving

Current sexual assault DNA testing is slow, manual, and unable to meet demand. Millions of victims wait for justice. The global forensic DNA market is growing at a double-digit CAGR; however, case prioritisation tools near victims or the scene of the crime, as well as laboratory and data automation in this critical workflow, are lacking.   

While technology has advanced rapidly, forensic DNA laboratories in most countries are still using legacy solutions that hinder their ability to reach their full potential.

HIGH TURNAROUND TIME

On average, a DNA sample collected from a victim takes over 3 months to process (from sample collection to reporting a result). 

SAMPLE BACKLOGS

Samples can take up to two months to reach the lab, risking evidence loss and compromising the chain of custody, while the perpetrator remains free.

LABORATORY PROCESS

Today’s lab process is slow, complex, and resource-intensive, requiring skilled staff and infrastructure, yet over half of the samples yield no usable results. 

INVESTIGATIVE LEADS

Currently available solutions for Decentralised DNA testing (Rapid DNA) are expensive, not fit for purpose, and fail to give context-specific information (meta-data) that can generate high-quality and impactful investigative leads. 

VELLIXIS PROGRAM

Introducing Biosecure ID's Vellixis Program

 

  • Vellixis Program: Automated Differential Extraction, powered by SpermX™ Nanofiber, delivering DNA profiles in <1 day (vs. 14 days)

  • Market Entry: £20M serviceable market across US, EMEA, APJ, and India

  • Scalable Growth: Expanding into £300M Human ID and £2B applied genomics markets

SpermX™ is protected by US Patents held by Innogenomics Technologies LLC, USA.

Learn More about Vellixis 📅
Evidence to Answers

1 We streamline workflows by separating cell types, simplifying deconvolution of mixed DNA, and extracting metadata, delivering clarity on DNA sources and deposition to solve complex forensic cases. 

Roadmap to Reduce workflow Gaps
2 We offer an innovative, practical DNA extraction solution for crime labs, aiming for global adoption and building toward a universal DNA analysis platform through ongoing development and investment. We reduce the time to result from Weeks to days and from a day to hours through our Vellixis and UDAP Programs.  Duing these two phases, Biosecure ID will build its own portfolio of defensible tech and competitive advantage.
Platform Agnostic Prototypes A & B

Vellixis Early Development

Biosecure ID has developed and tested multiple functional prototypes across core forensic and applied genomics workflows. Early laboratory data and partner-led evaluations show promising results, including improved sample handling, recovery, and workflow efficiency compared with existing approaches. These outcomes have validated key technical assumptions and informed design refinements toward manufacturable formats.

With prototypes operating in controlled settings, the company is positioned to move from proof of concept to further product development and scale up manufacturing.

GET STARTED LEARN MORE
Slide 14 Proof of Concept Studies-1
Slide 11 - manufacturing
Funding will Accelerate

Early Proof of Concept to Product Release

Biosecure ID has progressed from concept and prototyping to early internal (developmental) validation, followed by external alpha and beta test sites and downstream manufacturing at scale.

Your investment will support design-for-manufacture optimisation, supply-chain and inventory readiness, pilot deployments, and quality and regulatory groundwork required for early commercialisation.  Additionally, your funding will help with go-to-market execution and grow the install base.

 

Seed Round Open | $1.5m Target

 

LET'S CHAT LEAR MORE
HubSpot Campaign Material
BIGGER PICTURE

Getting Closer to Point of Need.

DNA Databases globally have expanded to approximately 120 million DNA profiles across the globe and it is geared to double by 2035.  With large offender population already on DNA Databases, the hit rate has touched 40% global mark and in some countries it is closer to 50%.

Decentralizing DNA testing closer to the point of need (whether it is scene of crime or at sexual assault referral centre) by authorised and trained professionals can be transformative.   Lern more about our Universal DNA Analysis Platform (UDAP) roadmap and support our programme over the next years.

LET'S CHAT
SEIS/EIS

HMRC Advance Assurance

Biosecure ID has obtained HMRC Advance Assurance Approval for eligible investments of up to £1M through SEIS/EIS scheme.   Some external resources are below thay explains the scheme further.

 

https://www.gov.uk/guidance/venture-capital-schemes-apply-to-use-the-seed-enterprise-investment-scheme

Join Biosecure ID now to get in early on our Universal DNA Analysis Platform

A clear and bold heading

DETAILS

Customize metrics to create your story

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ultricies leo integer malesuada nunc vel risus commodo viverra. At erat pellentesque adipiscing commodo elit at.

LET'S CHAT LEAR MORE
IMPORTANT BITS

Our Commitment to Confidentiality, IP & Privacy

  • Investment Disclaimer

  • Confidentiality

  • Intellectual Property

  • Privacy & Data

Investment Disclaimer

Any discussion of potential investments is for informational purposes only and does not constitute an offer, solicitation, or recommendation to invest. Investments involve risk, including loss of capital.

 

  © 2025, Biosecure ID Limited – All rights reserved.

Confidentiality

By scheduling this call, you agree that all information shared during the meeting is confidential and may not be disclosed to third parties without prior written consent from Biosecure ID.

 

  © 2025, Biosecure ID Limited – All rights reserved.

Intellectual Property

Any ideas, materials, or information shared are the intellectual property of Biosecure ID unless otherwise agreed in writing. Sharing or using these materials without permission is prohibited.

 

© 2025, Biosecure ID Limited – All rights reserved.

LEARN MORE LET'S CHAT

Privacy and Data

Your personal information will be used solely to schedule and manage this meeting, in accordance with our Privacy Policy. 

 

More details on our website:  https://biosecureid.com/privacy-policy/